SCHEMBL8937204

SCHEMBL8937204

CCc1c[nH]c(=O)c2ccc(OC3CCN(Cc4cccc(Cl)c4)CC3)c(F)c12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.49
MAOB P27338 2/20 0.49
HRH1 P35367 2/20 0.42
CCR3 P51677 2/20 0.42
SCN1A P35498 2/20 0.42
SCN8A Q9UQD0 2/20 0.42
OPRM1 P35372 1/20 0.41
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
CHRM2 P08172 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CHRM3 P20309 1/20 0.40
CYP2C19 P33261 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8937216 0.93 HRH1 (0.42) MAOAMAOBHRH1CCR3SCN1A
SCHEMBL13890296 0.90 ACHE (0.42) MAOAMAOBHRH1CCR3SCN1A
SCHEMBL8939062 0.89 HRH1 (0.41) MAOAMAOBHRH1CCR3SCN1A
SCHEMBL8937220 0.87 HRH1 (0.39) MAOAMAOBHRH1CCR3SCN1A
SCHEMBL8937227 0.86 ACHE (0.43) CCR3SCN1ASCN8AOPRM1ACHE
SCHEMBL8937636 0.85 MAOA (0.47) MAOAMAOBHRH1CCR3SCN1A
SCHEMBL8937219 0.85 OPRM1 (0.41) HRH1CCR3SCN1ASCN8AOPRM1
SCHEMBL8937221 0.84 SCN8A (0.41) SCN8ACHRM2CHRM3KDM4EDRD2
SCHEMBL8936704 0.84 HRH1 (0.45) MAOAMAOBHRH1CCR3
SCHEMBL8937187 0.83 HRH1 (0.39) HRH1CCR3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385047-B1 Piperidinyl-substituted isoquinolone derivatives SANOFI SA (FR) 2013-05-29 EP disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-8188117-B2 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
EP-2385047-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI (FR) 2011-11-09 EP disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives SANOFI-AVENTIS (FR) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093518-A1 Piperidinyl-substituted isoquinolone derivatives MYLK2, MYLK, RHOT2 MAOA 2633/4885MAOB 2595/4885HRH1 2936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.